To include your compound in the COVID-19 Resource Center, submit it here.

Calm investment

Pulmatrix gets $14M round to fund Phase IIa data in COPD, cystic fibrosis

Venture investors expect a $14 million series B1 round for respiratory play Pulmatrix Inc. will get its lead candidate to

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE